medigraphic.com

2021, Number 3

<< Back Next >>

Enf Infec Microbiol 2021; 41 (3)

Rhinocerebral mucormycosis associated with diabetic ketoacidosis in a cardiac surgery operated patient

Alonso PNC, Vázquez GJA, Reyes GU, Aguilar FES, Reyes HKL, Carreón GJM, Aquino VDY, Candelas DE, Cuevas LL, Arista VA

Language: Spanish
References: 20
Page: 123-127
PDF size: 312.04 Kb.


ABSTRACT

Mucormycosis is a serious fungal infection, usually acute onset and often fatal when is affected the rhinocerebral region in patients with diabetic ketoacidosis or immunocompromised. We report the case of a 30-month-old boy, diagnosed with a congenital heart disease (tetralogy of Fallot). After his surgery he develop diabetic ketoacidosis and rhinocerebral mucormycosis.
In immunocompromised patients, there are alterations in the immune system at both the cellular and humoral levels, with decrease in the neutrophil phagocytic of activity and an opsonization inability. Furthermore, Rhizopus organisms have an enzyme, ketone reductase, which allows them thrive in acidic environments and high glucose levels as in patients with diabetic ketoacidosis.


REFERENCES

  1. Richardson, M., Koukila, K.P. y Shankland, G., “Rhizopus, Rhizomucor, Absidia, and other agents of systemic and subcutaneous zygomycoses”, en P.R. Murray, E.J. Baron, J.H. Jorgensen, M.A. Pfaller y R.H. Yolken (eds.), Manual of clinical microbiology, 9ª ed., Washington, American Society of Microbiology, 2007.

  2. Sugar, A., “Agents of mucormycosis and related species”, en G.L. Mandell, J.E. Bennet y R. Dolin (eds.), Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 7ª ed., Filadelfia, Churchill Livingstone, 2009, p. 259.

  3. Wiedermann, B.L., “Zygomycosis”, en R.D. Feigin, J.D. Cherry, G.J. Demmler-Harrison y S.L. Kaplan (eds.), Textbook of pediatric infectious diseases, 6ª ed., Filadelfia, Saunders, 2009.

  4. Brettholz, A.M. y Mccauley, S.O., “Mucormycosis: early identification of a deadly fungus”, Journal of Pediatric Oncology Nursing, 2018, 35 (4): 257-66. Disponible en: https://doi.org/10.1177/1043454218763092.

  5. Hammer, M.M., Madan, R. y Hatabu, H., “Pulmonary mucormycosis: radiologic features at presentation and over time”, ajr American Journal of Roentgenology, 2018, 210 (4): 742-747. Disponible en: https://doi. org/10.2214/AJR.17.18792.

  6. Frater, L.J., Hall, S.G. y Procop, W.G., “Histologic features of Zygomycosis”, Archives of Pathology & Laboratory Medicine, 2001, 125 (3): 375-378.

  7. Garbino, J., Myers, C., Ambrosioni, J. y Gumy, P.F., “Report of a successful treatment of pulmonary Cunninghamella bertholletiae infection with liposomal amphotericin and posaconazole in a child with gvhd and review of the literature”, Journal of Pediatric Hematology/ Oncology, 2010; 32 (2): 85-7. doi:10.1097/MPH. 0b013e3181c2bdce.

  8. Rüping, M.J., Heinz, J.W., Kindo, J.A., Rickerts, V., Lass, F.C., Beisel, C., Herbrecht, R. et al., “Forty-one recent cases of invasive zygomycosis from a global clinical registry”, Journal of Antimicrobial Chemotherapy, 2010, 65 (2): 296-302. Disponible en: https://doi.org/10.1093/ jac/dkp430.

  9. Robertson, A.F., Joshi, V.V., Ellison, D.A. y Cedars, J.C., “Zygomycosis in neonates”, Pediatr Infect Dis J, 1997, 16 (8): 812-815 [Medline].

  10. Skiada, A., Lass-Floerl, C., Climb, N., Ibrahim, A., Roilides, E. y Petrikkos, G., “Challenges in the diagnosis and treatment of mucormycosis”, Med Mycol, 2018, 56 (suppl.1): 93-101 [Medline].

  11. Otto, W.R., Pahud, B.A. y Yin, D.E., “Pediatrics mucormycosis: a 10 year systematic review of reported cases an review of the literature”, Journal of Pediatrics Infectious Diseases Society, 2019, 8 (4): 342-350.

  12. Corzo, L.D., Chora, H.L., Rodríguez, Z.A. y Walsh, T.J., “Diabetes mellitus as the major risk factor for mucormycosis in México: epidemiology, diagnosis and outcomes of reported cases”, Med Micol, 2018, 56 (1): 29-43.

  13. Erica, L., Teng, M. y Limper, H.A., “Pulmonary mucormycosis clinical features and outcomes infection”, Pulmonary and Critical Care Medicine, 2017, 45 (4): 443-448.

  14. Ajith Kumar, A.K. y Vikas, G., “Rhino-orbital cerebral mucormycosis”, Last Update, 2020.

  15. Rahal, E.M., Moreno, V.M. y Villa, N.J., “Mucormicosis rino-órbito-cerebral: experiencia de doce años”, Rev Otorrin Cir Cabeza Cuello, 2008, 68: 27-34.

  16. Nucci, M., Engelhardt, M. y Hamed, K., “Mucormycosis in South América: a review of 143 reported cases”, Review Mycoses, 2019, 62 (9): 730-738.

  17. Frater, L.J., Hall, S.G. y Gary, W., “Histology features of zygomycosis”, Archives of Pathology Laboratory Medicine, 2001, 125 (3): 375-378.

  18. Hammer, M.M., Madan, R. y Hatabu, H., “Pulmonary mucormycosis: radiologic features at presentation and over time”, ajr Am J Roentgenol, 2018, 210 (4):742-747 [Medline].

  19. Xiaoping, L., Haixia, R., Mingjiang, L., Liang, Z., Bo, Y. y Weidong, Z., “Case report pulmonary mucormycosis after heart-kidney transplantation treated with vats lobectomy: a case report”, Int J Clin Exp Med, 2018, 11 (11):12790-12795. Disponible en: www.ijcem.com.

  20. Valdez de la Torre, E., Martínez, B.M. y Morayta, R.A., “Mucormicosis ‘rinoorbitaria’ en niños con inmunosupresión. Serie de tres casos y revisión de la literatura, Rev Latin Infect Pediatr, 2020, 33 (1): 49-56.




2020     |     www.medigraphic.com